|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
14.120 -0.300 (-2.080%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 20,383,158 | -4.376% | 41,248,505 | 43,811,385 | 38,864,174 | 30,163,260 |
| Cost of Sales | (10,463,386) | -2.198% | (21,595,309) | (23,169,690) | (20,229,785) | (13,733,529) |
| Gross Profit | 9,919,772 | -6.570% | 19,653,196 | 20,641,695 | 18,634,389 | 16,429,731 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (38,038) | -34.390% | (131,927) | (65,369) | (74,016) | (104,836) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 841,320 | -17.700% | 2,184,849 | 1,835,146 | 1,789,137 | 1,580,335 | |
| Profit / (Loss) before Taxation | 1,931,201 | -27.443% | 3,276,908 | 4,580,552 | 6,042,670 | 4,677,846 | |
| Taxation | (381,469) | -37.489% | (369,504) | (626,918) | (1,066,401) | (737,865) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (324,933) | 21.356% | (508,798) | (216,659) | (247,558) | (277,168) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,224,799 | -31.332% | 2,398,606 | 3,736,975 | 4,728,711 | 3,662,813 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 520,576 | 20.537% | 961,186 | 681,172 | 588,755 | 681,343 |
| Depreciation & Amortisation | 1,546,990 | -1.151% | 3,202,753 | 2,496,331 | 1,948,448 | 1,728,137 |
| Directors' Emoluments | -- | -- | 48,086 | 50,007 | 39,627 | 31,033 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 46.000 | -31.343% | 90.000 | 143.000 | 185.000 | 143.000 |
| DPS (cts) | 0.000 | -- | 27.000 | 42.000 | 56.000 | 43.000 |
| Dividend Payout Ratio (%) | -- | -- | 30.000% | 29.371% | 30.270% | 30.070% |
| Cash flow per share ($) | -- | -- | 1.279 | 1.618 | 1.536 | 1.007 |
| NBV per share ($) | 17.561 | -- | 17.081 | 16.665 | 15.271 | 14.413 |
| Remarks: | Real time quote last updated: 28/11/2024 15:05 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,224,799 |
| %Change | -31.332% |
| EPS / (LPS) | RMB 0.460 |
| NBV Per Share (¥) | RMB 17.561 |